Overview
- Eli Lilly and Insilico detailed a Monday announcement that pays $115 million up front with up to $2.75 billion tied to development, regulatory and commercial milestones plus royalties.
- The agreement gives Lilly exclusive global rights to a portfolio of Insilico’s preclinical oral therapeutics and sets new R&D programs that use Insilico’s Pharma.AI design platform.
- Insilico will join Lilly’s Gateway Labs community, and the licensed assets remain preclinical with future payments dependent on study results and regulatory decisions.
- The pact deepens earlier ties that began with a 2023 AI software license and expanded in 2025 with deals near $100 million, shifting from tool access to full development and commercialization rights.
- Insilico reports at least 28 AI-designed candidates with nearly half in clinical stages, while Lilly ramps AI dealmaking after strong sales of its tirzepatide drugs for diabetes and weight loss.